# REGENERON PHARMACEUTICALS INC Form SC 13G February 12, 2015

UNITED STATES SECURITIES EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934

Regeneron Pharmaceuticals, Inc. (Name of Issuer)

```
Common Stock
(Title of Class of Securities)
```

75886F107 (CUSIP Number)

December 31, 2014

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b) [] Rule 13d-1(c) [] Rule 13d-1(d)

CUSIP No. 75886F107

1.Names of Reporting Persons.

Sands Capital Management, LLC

I.R.S. Identification Nos. of above persons (entities only).

20-2830751

2. Check the Appropriate Box if a Member of a Group

(a) [ ] (b) [ ]

3.SEC Use Only

4.Citizenship or Place of Organization

Delaware, United States

Number of Shares Beneficially Owned by Each

Reporting Person With	
5.Sole Voting Po	ower 3,638,241
6.Shared Voting Power None	
7.Sole Dispositive Power 4,986,177	
8.Shared Dispositive Power None	
9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,986,177	
10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]	
11.Percent of Class Represented by Amount in Row (9) 5.0%	
12.Type of Reporting Person: IA	
Item 1(a).	Name of Issuer:
	Regeneron Pharmaceuticals, Inc.
Item 1(b).	Address of Issuer's Principal Executive Offices:
	777 Old Saw Mill River Road Tarrytown, NY 10591
Item 2(a).	Name of Person Filing
	Sands Capital Management, LLC
Item 2(b).	Address of Principal Business Office or, if None, Residence
	1101 Wilson Blvd. Suite 2300 Arlington, VA 22209
Item 2(c).	Citizenship
	Delaware, United States
Item 2(d).	Title of Class of Securities:
	Common Stock
Item 2(e).	CUSIP Number:
	75886F107
	Statement is Filed Pursuant to 240.13d-1(b) or 240.13d-2(b) Check Whether the Person Filing is a:
(b) - Ba (c) - Ir	coker or dealer registered under Section 15 of the Act. ank as defined in Section 3(a)(6) of the Act. asurance company as defined in Section 3(a)(19) of the Act. avestment company registered under Section 8 of the Investment Company Act of 1940.
	n investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); n employee benefit plan or endowment fund in accordance with

240.13d-1(b)(1)(ii)(F);

- (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an investment
- company under Section 3(c)(14) of the Investment Company Act of 1940; (j) - Group, in accordance with 240.13d-1(b)(1)(ii)(J).

#### Item 4. Ownership:

- a. Amount beneficially owned: 4,986,177
- b. Percent of Class: 5.0%
- c. Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote 3,638,241
  - (ii) Shared power to vote or to direct the vote None
  - (iii)Sole power to dispose or to direct the disposition of 4,986,177
  - (iv) Shared power to dispose or to direct the disposition None

Item 5. Ownership of Five Percent or Less of a Class:

Not Applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

[X]

Securities reported on this Schedule 13G are beneficially owned by clients of Sands Capital Management, LLC. Sands Capital Management, LLC clients may include investment companies registered under the Investment Company Act and/or employee benefit plans, pension funds, endowment funds or other institutional clients.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company of Control Person:

Not applicable.

Item 8. Identification and Classification of Members of the Group: Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10.Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date February 12, 2015

By:/s/ Lisa M. Grozio

Lisa M. Grozio Title: Chief Compliance Officer